#Coronavirus Disease Research #References (by AMEDEO, January 25 '25)

 

Antiviral Res

1. XU M, Zhang Z, Sun Y, Mai H, et al
   IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility.
   Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082.
   PubMed         Abstract available
   
   
2. CHUTIWITOONCHAI N, Akkarawongsapat R, Chantawarin S, Jiarpinitnun C, et al
   Antiviral effect of pinostrobin, a bioactive constituent of Boesenbergia rotunda, against porcine epidemic diarrhea virus.
   Antiviral Res. 2025;234:106073.
   PubMed         Abstract available
   
   

   
   BMJ

3. AGIUS RM
   Healthcare workers should get covid-19 vaccinations.
   BMJ. 2025;388:r89.
   PubMed        
   
   

   
   Graefes Arch Clin Exp Ophthalmol

4. KIM W, Park CM, Choi YJ, Kim DH, et al
   Recent trends and outcomes in immediate and delayed sequential bilateral cataract surgeries: a nationwide cohort study in South Korea.
   Graefes Arch Clin Exp Ophthalmol. 2025 Jan 20. doi: 10.1007/s00417-025-06737.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. RICCIO MD, Caini S
   Refining Influenza Epidemiology in the Post-COVID-19 Era: The Need for Complementary Approaches.
   Int J Infect Dis. 2025 Jan 18:107787. doi: 10.1016/j.ijid.2025.107787.
   PubMed        
   
   

   
   J Infect

6. SILVA SOUZA M, Pires Farias J, de Souza Ferreira LC, Amorim JH, et al
   Declining COVID-19 vaccination coverage in Brazil: A global health warning.
   J Infect. 2025;90:106418.
   PubMed        
   
   
7. FENG S, Bibi S, Aley PK, Cappuccini F, et al
   Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
   J Infect. 2025;90:106423.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. SOLAR P, Sery O, Vojtisek T, Krajsa J, et al
   The Blood-Cerebrospinal Fluid Barrier as a Potential Entry Site for the SARS-CoV-2 Virus.
   J Med Virol. 2025;97:e70184.
   PubMed         Abstract available
   
   

   
   J Virol

9. CHEN R, Zhou G, Yang J, Yuan R, et al
   A novel neutralizing antibody recognizing a conserved conformational epitope in PDCoV S1 protein and its therapeutic efficacy in piglets.
   J Virol. 2025 Jan 22:e0202524. doi: 10.1128/jvi.02025.
   PubMed         Abstract available
   
   
10. HASEGAWA N, Nishimura M, Takamiya R, Ishimaru H, et al
    SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitope.
    J Virol. 2025 Jan 22:e0138924. doi: 10.1128/jvi.01389.
    PubMed        
    
    
11. LIANG R, Tian J, Liu K, Ma L, et al
    The cytoplasmic tail of IBV spike mediates intracellular retention via interaction with COPI-coated vesicles in retrograde trafficking.
    J Virol. 2025 Jan 22:e0216424. doi: 10.1128/jvi.02164.
    PubMed         Abstract available
    
    

    
    Life Sci

12. DE SOUZA ALG, da Silva Rosa Alves AL, de Sousa JC, Barbosa NC, et al
    Inactivated SARS-CoV-2 induces acute skeletal muscle damage in human K18-hACE2 transgenic mice.
    Life Sci. 2025 Jan 18:123404. doi: 10.1016/j.lfs.2025.123404.
    PubMed         Abstract available
    
    

    
    Travel Med Infect Dis

13. ALBY A, Power A, Flaherty GT
    Analysis of consular assistance provided to Irish citizens abroad, 2014-2023.
    Travel Med Infect Dis. 2025 Jan 20:102803. doi: 10.1016/j.tmaid.2025.102803.
    PubMed         Abstract available